Lung Cancer | Specialty

The IMpower150 Regimen

April 13th 2020

How Long to Continue Immunotherapy

April 13th 2020

Immunotherapy and Brain Metastatic Lung Cancer

April 13th 2020

PD-L1 Less Than 49%: Available Treatments

April 13th 2020

Progression on Immunotherapy: Treatment Approach

April 13th 2020

Therapy Approach for PD-L1 Over 50% Lung Cancer

April 13th 2020

Work-Up and Management of Nondriver Metastatic Lung Cancer

April 13th 2020

Adjuvant Osimertinib Succeeds in Phase III ADAURA Trial in EGFR+ NSCLC

April 13th 2020

The phase III ADAURA trial of adjuvant osimertinib in patients with EGFR mutation–positive non–small cell lung cancer has been unblinded due to “overwhelming efficacy.”

Managing Lung Cancer Patients Through the COVID-19 Pandemic: What to Know

April 13th 2020

Join top leaders in the lung cancer field as they share their insights on COVID-19 and how the pandemic is poised to have a significant impact on lung cancer treatment and the health care system on Thursday, May 14, 2020 at 8 PM EST.

FDA Grants Nivolumab/Ipilimumab Plus Chemo Priority Review in Frontline NSCLC

April 8th 2020

The FDA has granted a priority review designation to nivolumab plus ipilimumab and chemotherapy for use as a frontline treatment for patients with metastatic or recurrent non–small cell lung cancer.

Dr. Merritt on Robotic Lobectomy Versus VATS and Open Thoracotomy in NSCLC

April 7th 2020

Robert E. Merritt, MD, FACS, discusses the long-term oncologic outcomes of robotic lobectomy versus video-assisted thoracoscopic surgery and open thoracotomy in early-stage non-small-cell lung cancer.

Brigatinib Approved in Europe for Frontline ALK+ NSCLC

April 6th 2020

The European Commission has approved brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer.

Weekly Webinar Series Part 6: Managing Lung Cancer Patients Through the COVID-19 Pandemic

April 6th 2020

In part 6 of our weekly COVID-19 Webinar Series, our panel of experts will share the latest updates and insights on the novel coronavirus. Join us Wednesday, April 29, 2020 at 8 PM EST.

Dr. Bertino on Frontline Dacomitinib in Metastatic EGFR+ NSCLC

April 2nd 2020

Erin M. Bertino, MD, discusses the use of dacomitinib (Vizimpro) in the treatment of patients with non–small cell lung cancer with EGFR mutations and its place among other available EGFR TKIs.

Cancer Vaccine Hits Early Benchmark in NSCLC, But COVID-19 Halts Phase III Trial

April 2nd 2020

OSE-2101 met the primary endpoint in the predefined Step-1 analysis of the phase III Atalante 1 trial in patients with HLA-A2 positive non–small cell lung cancer after failure of anti–PD-1/PD-L1 agents.

Dr. Socinski on Recommendations for Molecular Testing in Lung Cancer

March 31st 2020

Mark A. Socinski, MD, discusses his recommendations for conducting molecular testing in lung cancer.

Dr. Chen on the Impact of the Pivotal IMpower133 Trial on SCLC

March 31st 2020

Hui-Zi Chen, MD, PhD, discusses how the IMpower133 trial has helped to propel the field of small-cell lung cancer forward.

RET Inhibition Research: Next Steps

March 30th 2020

The Future of RET Inhibition in Clinical Practice

March 30th 2020

RET Inhibitors in Development

March 30th 2020